InvestorsHub Logo
Followers 51
Posts 3973
Boards Moderated 0
Alias Born 03/20/2014

Re: None

Sunday, 03/10/2024 1:19:50 PM

Sunday, March 10, 2024 1:19:50 PM

Post# of 465090
Lest we forget...

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Health Canada Special Access Program (SAP) Authorizes ANAVEX®2-73 (blarcamesine) for patients after successful completion of Open-Label Extension (OLE) study

Granting of requests are also ongoing in United Kingdom and Australia – representing all regions of Rett Syndrome study participation

https://finance.yahoo.com/news/anavex-2-73-blarcamesine-receives-113000106.html

All my posts are my opinion only and shouldn’t be used for decisions regarding purchasing or selling.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News